TaiMed Biologics signs licensing pact with Ambrilia Biopharma
As per the terms of the agreement, TaiMed is responsible to pay a sum of $250,000 as an upfront payment and might pay up to $7.6m to Ambrilia
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.